ACIB GmbH, Austrian Centre of Industrial Biotechnology, Vienna, Austria.
Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.
Biotechnol J. 2021 Mar;16(3):e2000215. doi: 10.1002/biot.202000215. Epub 2020 Oct 7.
Pichia pastoris has emerged in the past years as a promising host for recombinant protein and biopharmaceutical production. In the establishment of high cell density fed-batch biomanufacturing, screening phase and early bioprocess development (based on microplates and shake flasks) still represent a bottleneck due to high-cost and time-consuming procedures as well as low experiment complexity. In the present work, a screening protocol developed for P. pastoris clone selection is implemented in a multiplexed microfluidic device with 15 μL cultivation chambers able to operate in perfusion mode and monitor dissolved oxygen content in the culture in a non-invasive way. The setup allowed us to establish carbon-limited conditions and evaluate strain responses to different input variables. Results from micro-scale perfusion cultures are then compared with 1L fed-batch fermentation. The best producer in terms of titer and productivity is rapidly identified after 12 h from inoculation and the results confirmed by lab-scale fermentation. Moreover, the physiological analyses of the strains under different conditions suggested how more complex experimental conditions are achievable despite the relatively easy, straight-forward, and cost-effective experimental setup. Implementation and standardization of these micro-scale protocols could reduce the demand for lab-scale bioreactor cultivations thus accelerating the development of protein production processes.
毕赤酵母在过去几年中已成为重组蛋白和生物制药生产的有前途的宿主。在建立高密度细胞分批生物制造工艺中,筛选阶段和早期生物工艺开发(基于微孔板和摇瓶)仍然是一个瓶颈,因为这些阶段的程序既昂贵又耗时,而且实验复杂性低。在本工作中,我们在一个具有 15μL 培养腔的多重微流控设备中实施了用于毕赤酵母克隆选择的筛选方案,该设备能够以灌注模式运行,并以非侵入性方式监测培养物中的溶解氧含量。该设置允许我们建立碳限制条件,并评估不同输入变量对菌株的响应。然后将微尺度灌注培养物的结果与 1L 分批发酵进行比较。从接种后 12 小时即可快速确定在效价和生产力方面表现最佳的生产菌株,并通过实验室规模发酵进行验证。此外,对不同条件下菌株的生理分析表明,尽管实验设置相对简单、直接且具有成本效益,但仍可以实现更复杂的实验条件。这些微尺度方案的实施和标准化可以减少对实验室规模生物反应器培养的需求,从而加速蛋白质生产工艺的开发。